# Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

> **NCT00099255** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 40 (—)

## Conditions studied

- Large Cell Lymphoma

## Interventions

- **DRUG:** SGN-30

## Key facts

- **NCT ID:** NCT00099255
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 40 (—)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099255, "Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00099255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*